Presence of gene mutations in patients with pap... - Thyroid UK

Thyroid UK

137,139 members160,827 posts

Presence of gene mutations in patients with papillary thyroid cancer are associated with more aggressive cancer

Clutter profile image
3 Replies

BACKGROUND

Papillary cancer is the most common thyroid cancer. While most patients with this cancer have an excellent prognosis, a few patients do not do well, with recurrent cancer that requires more aggressive therapy. Many investigators are studying to identify which type of papillary thyroid cancers are more aggressive. The focus of these studies is on mutations in cancer-associated genes, especially a gene known as BRAF. Mutations in another cancer-associated gene TERT was recently found to be common in anaplastic thyroid cancer and poorly differentiated thyroid cancer. This study was undertaken to find out the effect of BRAF and TERT gene mutations on prognosis of patients with papillary thyroid cancer.

THE FULL ARTICLE TITLE:

Xing M et al. BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. J Clin Oncol. July 14, 2014 [Epub ahead of print].

SUMMARY OF THE STUDY

This study included 507 patients who had surgery for papillary thyroid cancer at the Johns Hopkins Hospital between 1990 and 2012 and were followed for average of 2 years. Thyroid cancer specimens from each patient were obtained and examined for the presence of a mutations in the BRAF or TERT gene or mutations in both genes. A mutation in the BRAF gene was detected in 38% and the TERT mutation in 12% of all 507 patients. Cancer recurred in 26% of patients with BRAF mutation and in 57% of patients with TERT mutation while recurrence was seen in 10% without BRAF mutation and in 11% of patients without TERT mutation. The risk of recurrent cancer was 3.1 times higher in patients with BRAF mutation and 3.3 times higher in patients with TERT mutations as compared to patients without BRAF or TERT mutations. The presence of both BRAF and TERT mutations were associated with larger cancers and the spread of cancer into surrounding tissue as well as outside of the neck. In addition, 69% of patients with both BRAF and TERT mutations had recurrent cancer. The life expectancy was lower in patients with BRAF or TERT mutations and was lowest in patients with both BRAF and TERT mutations as compared to patients without BRAF or TERT mutations.

WHAT ARE THE IMPLICATIONS OF THIS STUDY?

Detection of mutations in cancer-associated genes BRAF and TERT may identify the few number of patients with papillary thyroid cancer that have a worse prognosis. The authors of this study suggest that cancers that contain mutations in the BRAF and TERT genes require more aggressive treatment, although that needs to be studied.

thyroid.org/patient-thyroid...

Written by
Clutter profile image
Clutter
To view profiles and participate in discussions please or .
Read more about...
3 Replies
Clutter profile image
Clutter

Thanks, me.

Holly-43 profile image
Holly-43

Interesting reading, thank you. Is the BRAF mutation routinely tested on newly diagnosed Papillary cancer patients in the UK? If not can it be tested if requested on NHS patients?

Clutter profile image
Clutter in reply to Holly-43

Holly-43,

I don't know. I think you'll have to ask your surgeon.

You may also like...

post Papillary Thyroid Cancer

apparently now cancer free. Was not able to have RAI as had apparently had thyroiditis (picked up...

Give more funding for thyroid research and patients after price hike

share widely. Thyroid disease does not get sufficient funding despite being very common, this may...

Why is totally suppressed TSH only for post thyroid cancer patients

often times want post thyroid cancer patients to have a suppressed TSH to keep cancer from...

Evidence that T3 may be required by some people

absolutely the case, and it even identifies a genetic polymorphism that is associated with this....

Interesting study on T3 and vasodilation

not. This study shows that T3 acting via TRα1 receptors causes vasodilation without gene expression